Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Part of Head and Neck Cancer

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Nasopharyngeal Carcinoma

10 trials tracked for Nasopharyngeal Carcinoma: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 18 citations.

10Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 7 Other / NA 1
  1. Phase 3 A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients Completed · 18 cited
  2. Phase 4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed
  3. Phase 2 Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) Completed
  4. Phase 2 A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma Completed
  5. Phase 2 Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma Completed
  6. Phase 2 Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Completed
Show 4 more trials
  1. Phase 2 Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma Completed
  2. Phase 2 SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. Completed
  3. Phase 2 Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy Completed
  4. N/A NBI to Detect Post-RT Mucosal Residual NPC Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Nasopharyngeal Carcinoma: what the trials found

Current established evidence for nasopharyngeal carcinoma includes the use of stereotactic body radiotherapy 2. Additionally, autologous EBV specific Cytotoxic T cells were evaluated in a Phase 3 trial; however, the results did not show a statistically significant difference in Overall Survival (OS) for subjects with advanced disease (p=0.1942) 3.

Recent results — preliminary, needs further review

  • Nivolumab was evaluated in a Phase 2 study where patients reported a mean change of 3.7 on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP) scale, with 100% of participants experiencing acute and late toxicities 1.

For the clinician treating this condition

  • Stereotactic body radiotherapy is an established intervention for this condition 2.
  • Autologous EBV specific Cytotoxic T cells did not demonstrate a statistically significant impact on Overall Survival in advanced cases 3.

AI synthesis of 3 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
Oncology Phase II
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…
Apr 13, 2026
MRLN sparing radiotherapy shows non-inferior survival, reduced toxicity in nasopharyngeal carcinoma
Oncology RCT
MRLN sparing radiotherapy shows non-inferior survival, reduced toxicity in nasopharyngeal carcinoma New Radiation Plan Saves Swallowing Power
A phase 3 RCT of 568 adults with untreated, non-metastatic nasopharyngeal carcinoma found MRLN sparing radiotherapy was non-inferior to stan…
A new radiation plan for throat cancer lets patients skip a specific area, helping them keep their swallowing strength and eat normally for …
Apr 11, 2026
Meta-analysis finds Qi-deficiency constitution most prevalent in nasopharyngeal carcinoma health states
Oncology Meta-analysis
Meta-analysis finds Qi-deficiency constitution most prevalent in nasopharyngeal carcinoma health states Study finds link between Chinese medicine body types and nasopharyngeal cancer
A meta-analysis of 11 studies including 1,174 patients across nasopharyngeal carcinoma (NPC) health states found Qi-deficiency constitution …
A new analysis of 1,174 patients shows that a 'Qi-deficiency' body type is linked to Epstein-Barr virus infection and nasopharyngeal cancer.
Apr 2, 2026
Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC
Oncology Meta-analysis
Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC For advanced nasopharyngeal cancer, can immune therapy help? New analysis shows what patients might expect
A meta-analysis of 9 studies (883 patients) found PD-1/PD-L1 inhibitors for recurrent/metastatic nasopharyngeal carcinoma yielded a median O…
For advanced nasopharyngeal cancer, immune therapy helps 43% stay cancer-free for a year while 80% survive, though side effects affect 90% o…
NEJM Mar 30, 2026

Research across Head and Neck Cancer

Related studies from across the Head and Neck Cancer family.

Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
Oncology RCT
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Apr 13, 2026

Questions about Nasopharyngeal Carcinoma

Can saliva samples help predict if I have nasopharyngeal carcinoma or other cancers?

Yes, saliva samples can help predict nasopharyngeal carcinoma (NPC) risk by detecting EBV markers and microbial changes, but they are not yet standard for other cancers.

Full answer →
Did taking intravenous vitamin C help reduce stomach problems during chemotherapy for nasopharyngeal carcinoma?

No, intravenous vitamin C did not reduce stomach problems during chemotherapy for nasopharyngeal carcinoma in a clinical trial.

Full answer →
What viral markers are linked to a higher risk of getting nasopharyngeal carcinoma?

Antibodies to Epstein-Barr virus (EBV) proteins, especially EBNA1, and circulating EBV DNA are linked to higher NPC risk.

Full answer →
Does helical tomotherapy reduce dry mouth side effects in nasopharyngeal carcinoma patients?

Yes, helical tomotherapy (a form of IMRT) significantly reduces dry mouth (xerostomia) in nasopharyngeal carcinoma patients by sparing salivary glands, with low rates of severe xerostomia.

Full answer →
Can a specific saliva test accurately predict my risk for nasopharyngeal carcinoma?

Yes, a specific saliva test measuring IgA antibodies to EBNA1 protein can accurately predict NPC risk, with sensitivity up to 90% and specificity over 91%.

Full answer →
See all 5 questions about Nasopharyngeal Carcinoma →